Unaudited financial results for the quarter ended 31st December, 2005
(Rs. In Lacs)
PARTICULARS
Three
Three
Nine
Nine
Year
months
months
Months
Months
Ended
31.12.05
31.12.04
31.12.05
31.12.04
31.03.2005
Unaudited
Unaudited
Unaudited
Unaudited
Audited
Net Sales/Operational Income
8235.49
6674.68
24260.56
15622.73
23944.93
Others Income
34.09
2.92
98.05
35.36
57.50
TOTAL EXPENDITURE :
6571.64
5254.82
19631.68
12458.68
19582.77
(a) (Increase)/decrease in stock in trade
(36.19)
-346.55
(878.48)
-1227.46
-932.80
(b) Consumption of Raw Material
5019.34
4565.65
16211.81
10654.27
16300.63
(c) Staff Cost
189.76
56.63
479.77
293.68
441.83
(d) Other expenditure
1398.72
979.10
3818.58
2738.19
3773.11
Interest
299.83
220.71
815.46
584.14
830.54
Depreciation
233.02
103.87
582.74
286.84
409.85
Profit(+)/Loss(-) before tax
1165.10
1098.21
3328.74
2328.43
3179.27
Provision for taxation
98.04
98.17
280.11
194.64
260.27
Net Profit/Loss before Deferred Tax
1067.05
1000.03
3048.63
2133.79
2919.00
Provision for deferred tax
155.11
246.96
302.24
392.46
271.04
Provision for Fringe Benefit Tax
1.55
0.00
4.55
0.00
0.00
Net Profit/Loss
910.40
753.07
2741.84
1741.33
2647.96
Paid up Equity Share Capital
2090.00
1783.87
1840.00
Reserve excluding revaluation reserves
15080.58
7659.32
8874.14
EPS Rs. (Not Annualised)
- Basic
4.69
4.77
14.14
11.03
16.17
- Diluted
4.40
4.46
13.26
10.31
15.64
Aggregated on Non-Promoters Shareholding
No. of Shares
% of Shareholding
15504594
74.18%
13004594
72.90%
13004594
70.68%
Notes:
a) During the Quarter under review the Total turnover increased by 23.38% whereas the Export turnover increased by 22.24%. The net profit after tax increased by 20.89% over the corresponding figures of the previous year quarter.
b) In our efforts to tap the regulated markets, the Company has filed 6 DMFs in US and taergets to file 4 - 5 DMFs every year from FY 2006-07 onwards.
c) The Company has filed 13 patents for non-infringing process for its APIs in US$.
d) The company has put to commercial launch 4 new APIs during the quarter.
e) Information on Investor Complaints for the quarter:Opening Balance Nil, Received 2, Redressed 2, closing Balance Nil.
f) The previous period figures have been re-grouped and re-arranged wherever necessary.
g) The Company is exclusively in the Pharmaceutical business segment.
h) The above results were taken on record by the Board of Directors in its meeting held on 24th January, 2006.
For Ind-Swift Laboratories Limited
Sd/-
Sd/-
Place:Chandigarh
(N.R.MUNJAL)
(V.K.MEHTA)
Date: 24th January, 2006
Managing Director
Jt.Managing Director
To know about our Formulation Division, please visit us at Ind-Swift Limited, our other group company.
